Study: Cholesterol was lowered with an oral PCSK9 inhibitor.

Published Date: 08 Mar 2023

A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...

Read Full News

Latest News

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

News All Time

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class Linda Stein Gold, MD, Andrew Blauvelt, MD

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD Eric Simpson, MD, MCR

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD Aaron R. Mangold, MD

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

EADV Congress 2026: 9 Late Breakers to Know

EADV Congress 2026: 9 Late Breakers to Know

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Recommended News For You

Bayer is transforming pharmaceutical research into women's health

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, study finds

SBRT May Beat Brachytherapy in Prostate Cancer

Recommended Articles For You

What Is Carboxyhemoglobin And How Can It Affect Your Health? 

Blood-Cell Morphology Foundation Models: Transforming Hematological Diagnostics and Clinical Practice 

Modern Updates in Hematology in the Digital Era 

Immune Niches Supporting Tumor Dormancy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

2.

Virtual Reality Travel Reduces Cancer Pain.

3.

Teclistamab Alone Ups Previously Treated Myeloma Survival

4.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

5.

Oleanolic acid from grapes may increase chemotherapy effectiveness

1.

Clinical Guidelines for Cancer-Associated Thrombosis Monitoring

2.

Altered Bone-Marrow Microenvironment Dynamics During Ineffective Hematopoiesis

3.

Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment

4.

Treatment-Related Immune Dysfunction and Infection Risk in Cancer

5.

Managing Symptom Support During Cancer Treatment Transitions

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Clinical Insights in Oncology

2.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

4.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot